These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11103251)

  • 1. [The strategy of combination phase I/II study].
    Murakami H; Ohe Y; Saijo N
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 3. [A combination phase I/II study--dose escalation plan].
    Yamamoto N
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction of anticancer agents to phase I clinical trials].
    Shimoyama M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Challenges and concerns in early-phase clinical trials].
    Gordin A; Scheinin H
    Duodecim; 1992; 108(11):1026-36. PubMed ID: 1366021
    [No Abstract]   [Full Text] [Related]  

  • 9. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical assessment of international clinical development programmes for new antihypertensive drugs.
    Ménard J
    J Hypertens Suppl; 1993 Dec; 11(5):S39-46. PubMed ID: 8158432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development plan: N-Acetyl-l-cysteine.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():63-73. PubMed ID: 7616754
    [No Abstract]   [Full Text] [Related]  

  • 12. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
    Thall PF; Russell KE
    Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
    Chang SM; Reynolds SL; Butowski N; Lamborn KR; Buckner JC; Kaplan RS; Bigner DD
    Neuro Oncol; 2005 Oct; 7(4):425-34. PubMed ID: 16212807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early clinical trials in ECTG. Early Clinical Trial Group].
    Ogawa M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):238-41. PubMed ID: 8611053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New concepts for phase I trials: evaluating new drugs combined with radiation therapy.
    Deutsch E; Soria JC; Armand JP
    Nat Clin Pract Oncol; 2005 Sep; 2(9):456-65. PubMed ID: 16264990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.